TY - JOUR
T1 - How common are myeloproliferative neoplasms? A systematic review and meta-analysis
AU - Titmarsh, Glen J.
AU - Duncombe, Andrew S.
AU - Mcmullin, Mary Frances
AU - O'Rorke, Michael
AU - Mesa, Ruben
AU - De Vocht, Frank
AU - Horan, Sarah
AU - Fritschi, Lin
AU - Clarke, Mike
AU - Anderson, Lesley A.
PY - 2014/5
Y1 - 2014/5
N2 - Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs.
AB - Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs.
UR - http://www.scopus.com/inward/record.url?scp=84900866397&partnerID=8YFLogxK
U2 - 10.1002/ajh.23690
DO - 10.1002/ajh.23690
M3 - Article
C2 - 24971434
AN - SCOPUS:84900866397
SN - 0361-8609
VL - 89
SP - 581
EP - 587
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 6
ER -